Clinical trials are more complex than ever.
And 85% of them are delayed.
More screening criteria, more procedures, new vendor systems and tools, and more data. So who bears the burden of all this progress? Sites.
Increased site burden means degraded performance, more delays, and more problems for you. But it doesn't have
CHARLOTTESVILLE, VA Apr. 21, 2021 -- ArcheMedX announced today that ValenzaBio, a biotech focused on developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, has selected Ready, the industry’s leading clinical trial learning and predictive analytics platform, to optimize performance on its upcoming Phase II study.
ValenzaBio is deploying Ready to
ArcheMedX, a leader in behavior-based learning and operational insights for life sciences organizations, announced the release of two new whitepaper companions to its recent report, “COVID-19's Impact on Virtual Tech in Clinical Trials.” These whitepapers, focused on clinical research organizations and clinical trial sponsors, respectively, are intended to be playbooks
ArcheMedX today announced its on-going collaboration with PRA Health Sciences in a highly anticipated joint case study at the 2020 Clinical Trial Innovations Summit.
On Wednesday, 11 November, Kelly Ritch, EVP of Product and Clinical Solutions at ArcheMedX, will join Susan Zakarian, Sr. Manager of PRA Health Sciences to co-present a
Women of Color in Pharma (WOCIP) has emerged as a leading organization teaching our industry how to empower women of color through bold action.
Their value to all of us is best explained in their “Our Why” statement, where they commit to “Creating a nurturing and safe environment for self-reflection and